<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686608</url>
  </required_header>
  <id_info>
    <org_study_id>eIRB #938</org_study_id>
    <secondary_id>791</secondary_id>
    <nct_id>NCT00686608</nct_id>
  </id_info>
  <brief_title>Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients</brief_title>
  <official_title>Hypothalamic fMRI Response to Nutrients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify how certain parts of the brain that control appetite
      respond to changes in dietary carbohydrate and fat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To measure fMRI signal change in hypothalamic and brainstem centers associated with control
      of food intake and energy expenditure in response to IV glucose, fructose, and saline. The
      fMRI response to these nutrients will then be compared in obese vs. lean subjects. Frequently
      timed blood samples will be obtained for measurement of nutrients (i.e., glucose) and blood
      levels of other factors (i.e., insulin, ghrelin, lactate) during these infusion protocols,
      and to test associations between these levels and the fMRI response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2006</start_date>
  <completion_date type="Actual">July 1, 2015</completion_date>
  <primary_completion_date type="Actual">July 1, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will receive infusions of glucose, fructose, and saline in a randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcomes of this aim will be the change in fMRI response in the hypothalamus to IV glucose, to IV glucose during intralipid infusion, and to the IV glucose alone, in the lean and obese groups separately.</measure>
    <time_frame>0,1,2 and 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glucose</intervention_name>
    <description>0.3mg/kg of glucose</description>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fructose</intervention_name>
    <description>fructose IV bolus</description>
    <arm_group_label>Fructose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>IV saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 year to 45 years of age

          -  BMI 18 to 25 kg/m2 (25 subjects) and 30 to 40 kg/m2 (25 subjects), matched for age and
             sex.

          -  At maximal lifetime weight.

          -  Weight stable for at least 3 months.

        Exclusion Criteria:

          -  Those with a major medical illness or who require prescription medication, including:
             cancer, coronary artery disease, hypertension, and diabetes.

          -  Subjects taking psychiatric or centrally-acting (CNS) medications, or who are
             diagnosed with a psychiatric or neurological illness, including: depression, anorexia,
             bulimia, and seizure disorder.

          -  Subjects who have lost weight as a result of dieting, pharmacological treatment, or
             bariatric surgery.

          -  Weight &gt; 350 lbs or girth &gt; 60 inches (the limits of the MR machine)

          -  Exercise &gt; 30 minutes, 3 times a week.

          -  Alcohol consumption &gt; 2 drinks / day.

          -  Weight &gt; 300 lbs (150 kg) (weight limit for MR machine).

          -  Blood glucose &gt; 100 mg/dL, abnormal creatinine or liver function tests.

          -  Illicit drug use.

          -  Pregnancy.

          -  Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary
             carbohydrate, protein, or fat intakes.

          -  Those with a contraindication to exposure to strong magnetic fields: presence of metal
             in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips.

          -  Those with claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Q. Purnell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jonathan Purnell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

